Credit: Getty Images. Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with ...

The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC). A new report is shedding light on how some ...

The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to ...

The addition of ivosidenib (Tibsovo) to azacitidine led to a threefold survival improvement for newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients who were ineligible for intensive ...

Impact of value frameworks on the magnitude of clinical benefit: Evaluating a decade of randomized trials for systemic therapy in solid malignancies. Effect of enasidenib (ENA) plus azacitidine (AZA) ...

On the heels of a $278 million IPO, Forma Therapeutics is inching toward its first FDA filing. Its lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with acute myeloid leukemia ...

Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...

A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...

The FDA approved the IDH1 inhibitor olutasidenib (Rezlidhia) for relapsed or refractory acute myeloid leukemia (AML). The approved indication stipulates use of olutasidenib in relapsed/refractory AML ...

Credit: Getty Images. Rezlidhia is a small molecule inhibitor of mutated IDH1. Rezlidhia ™ (olutasidenib) is now available for the treatment of adults with relapsed or refractory acute myeloid ...